Lv1
10 积分 2026-04-08 加入
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
3小时前
已完结
Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS
5小时前
已完结
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
6小时前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
6小时前
已完结
Recent progress in developing ATR inhibitors as anticancer agents
19天前
已完结
An update on small molecule compounds targeting synthetic lethality for cancer therapy
21天前
已完结
皖公网安备34019202002308
